Biofrontera AG proposed revenue guidance for the year 2022. For the year, the company expects total revenues are expected to increase by at least 30% compared with 2021, including first quarter total revenues up by over 100% versus the first quarter prior year and typical seasonal strength in the first and fourth quarters.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2.97 EUR | -2.46% |
|
-2.14% | -64.73% |
24/06 | Biofrontera Announces the Launch of A New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp | CI |
31/05 | Biofrontera AG Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-64.73% | 1.93Cr | |
+55.19% | 81TCr | |
+47.26% | 65TCr | |
-6.09% | 35TCr | |
+21.92% | 34TCr | |
+18.40% | 25TCr | |
+3.64% | 23TCr | |
+12.98% | 22TCr | |
+10.86% | 17TCr | |
-2.78% | 16TCr |
- Stock Market
- Equities
- B8FK Stock
- News Biofrontera AG
- Biofrontera AG Proposes Revenue Guidance for the Year 2022